Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats

Background: Sotalol is a class III antiarrhythmic drug commonly used in various arrhythmia treatments. However, due to its potent potassium channel inhibition, it can prolong the QT interval and lead malignant arrhythmias. Empagliflozin an inhibitor of sodium‑glucose cotransporter 2 (SGLT2) has positive effect on cardiovascular outcomes. Since empagliflozin activation channels unknown, there no recommendation regarding coadministration these drugs. Aims: The study aimed evaluate possible protective effects sotalol‑induced prolongation. Methods: We randomized 24 rats into 4 groups. control group received only physiological saline, EMPA group, empagliflozin; SOT sotalol; EMPA+SOT sotalol. PR intervals heart rates were measured under anesthesia at baseline 1, 2, 3 hours II. Results: In QTc as well T‑wave duration statistically longer, whereas lower than (P < 0.001 for all parameters). ameliorated prolongation group. interval, duration, shorter, rate was greater 0.001, P = 0.002, respectively). Conclusion: significantly ameliorates could be safely with sotalol clinical practice. Future trials might recommend routine use prevent diabetic patients receiving